Nanobiotix S.A. (NBTX) Stock Forecast Oct. 30, 2026
Analysis updated on Oct. 30, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Nanobiotix S.A. (NBTX) stock forecast summary
This forecast was produced 3 trading days ago and has not been refreshed since; read it as historical, not as a current view.
Nanobiotix S.A. is a small-cap company with a market capitalization of $1.64B. It ranks number 60 by market capitalization among the 60 Pharmaceutical Preparations issuers in our coverage with a current forecast.
For NBTX, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -36.0%, measured on 89 forecast dates between 2026-03-31 and 2026-07-31 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -22.0%, measured on 132 forecast dates between 2026-03-31 and 2026-09-30. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.9%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-30 signals)
NBTX price chart and AI forecast
How NBTX ranks among 4891 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Nanobiotix S.A. (NBTX) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Pharmaceutical Preparations peers listed below that report each metric. Statement values were filed in EUR and are shown converted to USD (flows at the trailing twelve-month average rate, balances at the balance-sheet date rate).
Valuation & Market
| Metric | NBTX | Rank |
|---|---|---|
| Market Cap | $1.64B | 60/60 |
| EPS | $-2.86 | – |
| Revenue/Share | $1.09 | – |
| FCF/Share | $-1.77 | – |
Profitability & Margins
| Metric | NBTX | Rank |
|---|---|---|
| ROA | -148.0% | 42/42 |
| Operating Margin | -184.3% | 35/39 |
| Net Margin | -215.7% | 33/36 |
Financial Health
| Metric | NBTX | Rank |
|---|---|---|
| Current Ratio | 1.09x | 49/58 |
| Working Capital | $6M | 52/58 |
Cash Flow
| Metric | NBTX | Rank |
|---|---|---|
| Operating Cash Flow | -$84M | 42/59 |
| Free Cash Flow | -$86M | 36/50 |
| Capital Spending | -$2M | 13/50 |
| FCF/Sales | -162.3% | 39/42 |
| CapEx/Sales | 3.1% | 21/42 |
Operational Efficiency
| Metric | NBTX | Rank |
|---|---|---|
| Asset Turnover | 0.69x | 10/38 |
| Fixed Assets Turnover | 10.2x | 18/41 |
Income Statement
| Metric | NBTX | Rank |
|---|---|---|
| Total Revenue | $53M | 45/46 |
| Operating Income | -$97M | 31/51 |
| Net Income | -$114M | 28/47 |
| R&D Expense | $90M | 55/58 |
| SG&A Expense | $59M | 41/41 |
Dividend & Shareholder Information
| Metric | NBTX | Rank |
|---|---|---|
| Shares Outstanding | 48M | – |
Balance Sheet Highlights (USD millions, converted from EUR)
| Total Current Assets | $74M | |
| Cash & Short-term Investments | $62M | |
| Total Liabilities | $179M | |
| Short-term Debt | $57M |
NBTX quarterly financials and insider trading
Nanobiotix S.A. (NBTX) industry peers
Companies classified under the same SEC industry code as Nanobiotix S.A. (Pharmaceutical Preparations): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| NBTX Nanobiotix S.A. | $1.64B | |
| LLY Eli Lilly & Co | $1.33T | |
| JNJ Johnson & Johnson | $640.75B | |
| ABBV Abbvie Inc. | $521.11B | |
| MRK Merck & Co., Inc. | $356.93B | |
| NVS Novartis Ag | $303.89B | |
| AZN Astrazeneca Plc | $285.01B | |
| ABT Abbott Laboratories | $190.23B | |
| NVO Novo Nordisk A S | $177.76B | |
| PFE Pfizer Inc | $170.99B | |
| VRTX Vertex Pharmaceuticals Inc / Ma | $136.87B | |
| BMY Bristol Myers Squibb Co | $126.14B | |
| SNY Sanofi | $106.33B | |
| REGN Regeneron Pharmaceuticals, Inc. | $100.21B | |
| GSK Gsk Plc | $98.25B | |
| TAK Takeda Pharmaceutical Co Ltd | $62.51B | |
| TEVA Teva Pharmaceutical Industries Ltd | $48.84B | |
| ONC Beone Medicines Ltd. | $40.36B | |
| GMAB Genmab A/S | $36.34B | |
| ZTS Zoetis Inc. | $34.37B | |
| RPRX Royalty Pharma Plc | $28.77B | |
| ROIV Roivant Sciences Ltd. | $26.03B | |
| UTHR United Therapeutics Corp | $25.79B | |
| INSM Insmed Inc | $22.91B | |
| VTRS Viatris Inc | $21.44B | |
| ALNY Alnylam Pharmaceuticals, Inc. | $21.42B | |
| ASND Ascendis Pharma A/S | $16.43B | |
| JAZZ Jazz Pharmaceuticals Plc | $14.91B | |
| BBIO Bridgebio Pharma, Inc. | $14.42B | |
| SMMT Summit Therapeutics Inc. | $12.60B | |
| ELAN Elanco Animal Health Inc | $12.28B | |
| RDY Dr Reddys Laboratories Ltd | $11.83B | |
| BMRN Biomarin Pharmaceutical Inc | $10.77B | |
| TGTX Tg Therapeutics, Inc. | $9.22B | |
| MDGL Madrigal Pharmaceuticals, Inc. | $9.16B | |
| PTGX Protagonist Therapeutics, Inc | $9.07B | |
| CORT Corcept Therapeutics Inc | $8.86B | |
| SYRE Spyre Therapeutics, Inc. | $8.75B | |
| CYTK Cytokinetics Inc | $8.66B | |
| ARWR Arrowhead Pharmaceuticals, Inc. | $8.54B | |
| PRAX Praxis Precision Medicines, Inc. | $7.83B | |
| ALKS Alkermes Plc. | $7.67B | |
| KNSA Kiniksa Pharmaceuticals International, Plc | $7.33B | |
| AXSM Axsome Therapeutics, Inc. | $7.31B | |
| IONS Ionis Pharmaceuticals Inc | $7.23B | |
| ABVX Abivax S.A. | $6.97B | |
| ORKA Oruka Therapeutics, Inc. | $6.59B | |
| AMRX Amneal Pharmaceuticals, Inc. | $6.45B | |
| RYTM Rhythm Pharmaceuticals, Inc. | $6.37B | |
| LGND Ligand Pharmaceuticals Inc | $6.27B | |
| BLTE Belite Bio, Inc | $5.99B | |
| PTCT Ptc Therapeutics, Inc. | $5.69B | |
| MIRM Mirum Pharmaceuticals, Inc. | $5.61B | |
| MANE Veradermics, Inc | $5.58B | |
| COGT Cogent Biosciences, Inc. | $5.39B | |
| ERAS Erasca, Inc. | $5.12B | |
| DNTH Dianthus Therapeutics, Inc. /De/ | $4.63B | |
| TVTX Travere Therapeutics, Inc. | $4.42B | |
| INDV Indivior Pharmaceuticals, Inc. | $4.17B | |
| EWTX Edgewise Therapeutics, Inc. | $4.09B |
Where NBTX sits on the market map
Nanobiotix S.A. (NBTX) stock news
Loading...
Nanobiotix S.A. (NBTX) stock forecast FAQ
What is the Nanobiotix S.A. (NBTX) stock forecast?
This forecast was produced 3 trading days ago and has not been refreshed since; read it as historical, not as a current view.
How accurate are Nanobiotix S.A. stock predictions?
For NBTX, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -36.0%, measured on 89 forecast dates between 2026-03-31 and 2026-07-31 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -22.0%, measured on 132 forecast dates between 2026-03-31 and 2026-09-30. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Nanobiotix S.A. forecasts updated?
Nanobiotix S.A. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 30, 2026.
Which companies are Nanobiotix S.A.'s industry peers?
60 issuers in our coverage, NBTX included, share the SEC industry code Pharmaceutical Preparations. The largest are: Eli Lilly & Co (LLY), Johnson & Johnson (JNJ), Abbvie Inc. (ABBV), Merck & Co., Inc. (MRK), Novartis Ag (NVS), Astrazeneca Plc (AZN).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.